#Contract Research Development and Manufacturing Organization (CRDMO)

[neosciencehub]

India's Rising Role in the Global Pharmaceutical Supply Chain

India's Rising Role in the Global Pharmaceutical Supply Chain @neosciencehub #India #PharmaceuticalSupply #CRDMO #USFDA #neosciencehub

In recent years, India has cemented its position as a vital player in the global pharmaceutical landscape. This growth is largely driven by its Contract Research Development and Manufacturing Organization (CRDMO) sector, which is poised for significant expansion. A recent report by Macquarie Equity Research highlights key factors contributing to India’s growing attractiveness as a destination for…

[aitoolswhitehattoolbox]

Digital Marketing Manager (Remote)

Job Title: Digital Marketing ManagerDepartment: MarketingReporting To: Chief Marketing OfficerClassification: ExemptSalary: 80k-115k (Depending On Experience)What We DoBioduro is one of the premier Contract Research, Development and Manufacturing Organizations (CRDMO) globally, with more than 2,200 employees. Our US operations are US headquartered in Irvine, CA. Our 7 global facilities provide…

[impact-newswire]

BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer

Armin Spura, PhD, CEO, BioDuro-Sundia (Photo: Business Wire) IRVINE, Calif. – BioDuro-Sundia, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to announce the appointment of Dr. Armin Spura as its new Chief Executive Officer. Dr. Spura brings over two decades of experience in the life sciences and biotechnology sectors, with a proven track record of…

[tamanna31]

Small Molecule Innovator CDMO Market - The Biggest Trends to watch out for 2024-2030

Small Molecule Innovator CDMO Industry Overview

The global small molecule innovator CDMO market size was estimated at USD 48.6 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 6.21% from 2024 to 2030. Key drivers for this growth are increasing pharmaceutical R&D investment, growing demand for small molecules, and rising incidence of cancer & age-related disorders. Biological drugs are more expensive than small molecules. Hence, growing demand for cost-effective drugs is expected to further support market growth.

The COVID-19 pandemic significantly impacted on global economy in 2020 and caused an ongoing impact on various industries. However, the market for contract development and manufacturing organization (CDMO) witnessed a positive impact due to this pandemic. CDMOs played an important role in meeting the needs of pharmaceutical companies, biotech companies, and other end-users during this crisis. Overall, pandemic boosted market demand for small molecule innovator drugs. With the growing demand for outsourcing by pharma companies, heightened demand is observed in post-pandemic scenario.

Gather more insights about the market drivers, restrains and growth of the Small Molecule Innovator CDMO Market

Small Molecule Innovator CDMO Market Segmentation

Grand View Research has segmented the global small molecule innovator CDMO market based on product, stage type, customer type, therapeutic area, and region:

Small Molecule Innovator CDMO Product Outlook (Revenue, USD Million, 2018 - 2030)

Small Molecule API

Small Molecule Drug Product

Oral solid dose

Semi-Solid Dose

Liquid Dose

Others

Small Molecule Innovator CDMO Stage Type Outlook (Revenue, USD Million, 2018 - 2030)

Preclinical

Clinical

Phase I

Small

Medium

Large

Phase II

Small

Medium

Large

Phase III

Small

Medium

Large

Commercial

Small Molecule Innovator CDMO Customer Type Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceutical

Small

Medium

Large

Biotechnology

Small Molecule Innovator CDMO Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)

Cardiovascular disease

Oncology

Respiratory disorders

Neurology

Metabolic disorders

Infectious disease

Others

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global intrauterine devices marketsize was estimated at USD 6.25 billion in 2023 and is projected to grow at a CAGR of 3.66% from 2024 to 2030.

The global dual chamber prefilled syringes marketsize was valued at USD 167.3 million in 2023 and is projected to grow at a CAGR of 5.8% from 2024 to 2030.

Key Companies & Market Share Insights

Companies are undertaking various strategic initiatives to gain a competitive advantage. Key parameters affecting the competitive nature of the market include acquisition, geographic expansion, mergers, acquisitions, and product launches.

In September 2022, WuXi STA inaugurated a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its Wuxi city campus. The integrated drug product platform CRDMO provides a full range of services, including solid-state development, pre-formulation, and clinical to commercial drug product manufacturing.

In June 2022, Lonza inaugurated a new clinical phase development and manufacturing facility in its small molecules site in Bend, Oregon. It is dedicated to manufacturing bioavailability-enhancing spray-dried dispersion (SDD) finished dosage forms and drug product intermediates

List of Key Players of Small Molecule Innovator CDMO Market

Piramal Pharma Solutions

CordenPharma International

Wuxi AppTec

Cambrex Corporation

Recipharm AB

Pantheon (Thermo Fisher Scientific)

Lonza

Catalent Inc.

Siegfried Holding AG

Boehringer Ingelheim

Labcorp Drug Development

Order a free sample PDF of the Small Molecule Innovator CDMO Market Intelligence Study, published by Grand View Research.

[straitsresearchblogs]

Laboratory Informatics Market: Information by Product (Laboratory Information Management Systems (LIMS)), Delivery Mode, Component, End-Use,and Region —Forecast till 2029

Rapid technological advancement has made laboratory equipment less static and more interactive, enabling vast networks of interconnected laboratory instruments, computers, and telecommunication equipment to record, analyze, and distribute data. It also enables researchers to spend less time gathering data and waiting for information to arrive from one place to another. Laboratory informatics allows laboratories to remain competitive by providing reliable, robust, and scalable data management systems.

Grab a sample PDF here   https://straitsresearch.com/report/laboratory-informatics-market/request-sample

Shifting preference towards personalized medicine, rising research in cancer genomics, and growing requirements for patient involvement drive the market growth. Rising incidences of diagnostic errors are subsequently driving the demand for laboratory informatics. The World Health Organization (WHO)estimates that around 5% of patients in developing countries face diagnostic errors every year.  

The laboratory informatics market was valued at USD 2,650 million in 2019 and is expected to grow with a CAGR of 7.6% during the forecast period.

Laboratory automation is emerging as an essential approach, minimizing manual interference in laboratory processes. The automation of routine laboratory procedures, with the aid of dedicated workstations and system instruments software, increases laboratory efficiency and enables researchers to concentrate on important tasks and avoid human errors. Stringent regulations imposed on automation of laboratory procedures ensure optimum efficiency with error-free results, further driving the market growth.

As per the report in the Journal of Lab Automation, the error incidences in fully automated, semi-automated, and manual operations vary between 1–5%, 1–10 %, and 10–30%, respectively. Rising adoption of digital workstations, automated analyzers, and complete laboratory automation (TLA) enables the laboratory staff to be reassigned tasks and add higher value to the operations. Additionally, the surge in the data generated by laboratory systems is subsequently increasing the demand for effective methods to process, analyze, and share data, further driving the market growth.

Rising Demand for Fully Integrated Services to Drive the Laboratory Information Management Systems Segment

The laboratory information management systems (LIMS) segment is projected to dominate the market during the forecast period. The system offers master data management, sample lifecycle analysis, reliability research, system and security administration, schedules, inventory, equipment, logistics and storage space, and analytical workflow. Rising demand for fully integrated services in life sciences and research industries to reduce data processing errors drive the segment growth.

Cloud-Based Segment to Grow at a Fastest Rate

The cloud-based segment is projected to grow at the fastest rate on account of advancement in virtualization and the availability of high-speed internet. Cloud-based laboratory informatics eliminates the need for heavy capital investments in infrastructure and enables fast and safe data transfer within the organizations, further driving the segment growth.

Pharmaceuticals are developing a virtual network with contract research, production, and manufacturing organizations (CRDMOs) and academic institutions using centralized corporate-based facilities. The adoption of cloud-based technologies will enable these organizations to manage the massive amounts of produced data at economical costs. The integration of cloud-based models with laboratory informatics is projected to enhance data accessibility and provide real-time analysis at competitive prices, further driving the segment growth.

Lack of Resources and Expertise to Drive the Services Segment Growth

The services segment holds the largest market share due to the rising outsourcing of LIMS solutions. Currently, several pharmaceutical research laboratories lack the resources and expertise for analytics implementation, subsequently rising the outsourcing activities. TheCROs offers social media analytics, production procedure, preventive maintenance, predictive analytics for the failure of medical devices, and benchmarking solutions, further driving the segment growth

Life Sciences Industry Segment to Witness the Fastest Growth

The life sciences industry segment is projected to witness the fastest growth on account of rising demand for laboratory informatics to develop new products, boost product quality, and operational performance. Rising technical developments in the healthcare sector are subsequently increasing the adoption of laboratory informatics for patient interaction, management, billing, patient safety information monitoring, and quality assurance.

[sunilbutolia]

Sai Life Sciences Wins Golden Peacock National Training Award 2021 888011000 110888 HYDERABAD, India, July 26, 2021/ PRNewswire/-- Sai Life Sciences, one of India's fastest growing Contract Research, Development & & Manufacturing Organizations (CRDMOs), today revealed that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical category. This is the second consecutive Golden Peacock Award for the business following the Golden Peacock National Quality Award it received in 2020. Making the statement, Chief Quality Officer of Sai Life Sciences, Dr M Damodharan said, "Being in a knowledge-intensive industry, we promote the abilities and proficiencies of our individuals through best-in-class L&D practices covering holistic training, integrated governance, and user convenience. It is the determination with which our partners embraced the online training system that has actually permitted to sustain superior remarkable standards requirements over 99.5%in the last two years. I dedicate this prominent recognition to all Saimers." Golden Peacock Awards are the most desirable awards for corporate quality in India arranged every year under the aegis of the Institute of Directors, India. A grand jury under the chairmanship of Hon' ble Justice M. N. Venkatachaliah, previous Chief Justice of India and previous Chairman, National Human Rights Commission of India and National Commission for Constitution of India Reforms, had actually gotten 311 applications this year out of which 147 applications were shortlisted for numerous categories of awards including Business Excellence, Innovative Product/Service and Quality. Earlier this year, Sai Life Sciences won two awards at the prominent, US-based Association for Talent Development-Excellence in Practice(ATD-EIP)awards 2021 in categories of'Learning Technologies'and'Change Management'. The company has actually mapped the finding out requirements of over 100 distinct functions throughout the organization and provides holistic training across quality, technical, safety, soft abilities and more, with interactive audio-visual resources provided through a robust learning management system. Over the previous 3 years, the company has invested US$ 100M to broaden and update its R&D and production centers, induct superior worldwide clinical and leadership skill, strengthen automation and data systems, and above all raise the bar for safety, quality and consumer focus. With over two decades of experience in advancing its clients' drug discovery programs and current transformational investments, the business is today poised to play a more substantial role in speeding up the discovery, advancement, and production of complex little particles for innovator pharma and biotech companies. The company's dedication to finest practices of sustainability and principled governance have actually been recognized with an award at the distinguished 21st National Award for Excellence in Energy Management 2020 by CII-Sohrabji Godrej Green Business Centre, and a 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry(CII)South awards 2019. About Sai Life Sciences Sai Life Sciences is a full-service CRO / CDMO driven by a vision to support the launch of 25 new medications by 2025. It deals with innovator pharma and biotech business globally, accelerating the discovery, advancement, and manufacture of complicated small molecules. As a pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development programs, consistently providing worth based on its quality and responsiveness. Today, it deals with 7 of the leading 10 big pharma business, in addition to numerous small and mid-sized pharma & biotech companies. Sai Life Sciences is independently held and backed by internationalfinanciers, TPG Capital and HBM Healthcare Investments. www.sailife.com Picture: https://mma.prnewswire.com/media/1581107/Sai_Life_Sciences_Award.jpg Logo design: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

Sai Life Sciences Wins Golden Peacock National Training Award 2021 888011000 110888 HYDERABAD, India, July 26, 2021/ PRNewswire/– Sai Life Sciences, one of India’s fastest growing Contract Research, Development & & Manufacturing Organizations (CRDMOs), today revealed that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical category. This is the second consecutive Golden Peacock Award for the business following the Golden Peacock National Quality Award it received in 2020. Making the statement, Chief Quality Officer of Sai Life Sciences, Dr M Damodharan said, “Being in a knowledge-intensive industry, we promote the abilities and proficiencies of our individuals through best-in-class L&D practices covering holistic training, integrated governance, and user convenience. It is the determination with which our partners embraced the online training system that has actually permitted to sustain superior remarkable standards requirements over 99.5%in the last two years. I dedicate this prominent recognition to all Saimers.” Golden Peacock Awards are the most desirable awards for corporate quality in India arranged every year under the aegis of the Institute of Directors, India. A grand jury under the chairmanship of Hon’ ble Justice M. N. Venkatachaliah, previous Chief Justice of India and previous Chairman, National Human Rights Commission of India and National Commission for Constitution of India Reforms, had actually gotten 311 applications this year out of which 147 applications were shortlisted for numerous categories of awards including Business Excellence, Innovative Product/Service and Quality. Earlier this year, Sai Life Sciences won two awards at the prominent, US-based Association for Talent Development-Excellence in Practice(ATD-EIP)awards 2021 in categories of’Learning Technologies’and’Change Management’. The company has actually mapped the finding out requirements of over 100 distinct functions throughout the organization and provides holistic training across quality, technical, safety, soft abilities and more, with interactive audio-visual resources provided through a robust learning management system. Over the previous 3 years, the company has invested US$ 100M to broaden and update its R&D and production centers, induct superior worldwide clinical and leadership skill, strengthen automation and data systems, and above all raise the bar for safety, quality and consumer focus. With over two decades of experience in advancing its clients’ drug discovery programs and current transformational investments, the business is today poised to play a more substantial role in speeding up the discovery, advancement, and production of complex little particles for innovator pharma and biotech companies. The company’s dedication to finest practices of sustainability and principled governance have actually been recognized with an award at the distinguished 21st National Award for Excellence in Energy Management 2020 by CII-Sohrabji Godrej Green Business Centre, and a 5-Star rating for Excellence in EHS Practices at the Confederation of Indian Industry(CII)South awards 2019. About Sai Life Sciences Sai Life Sciences is a full-service CRO / CDMO driven by a vision to support the launch of 25 new medications by 2025. It deals with innovator pharma and biotech business globally, accelerating the discovery, advancement, and manufacture of complicated small molecules. As a pure-play CRO-CDMO, Sai Life Sciences has served diverse NCE development programs, consistently providing worth based on its quality and responsiveness. Today, it deals with 7 of the leading 10 big pharma business, in addition to numerous small and mid-sized pharma & biotech companies. Sai Life Sciences is independently held and backed by internationalfinanciers, TPG Capital and HBM Healthcare Investments. www.sailife.com Picture: https://mma.prnewswire.com/media/1581107/Sai_Life_Sciences_Award.jpg Logo design: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

HYDERABAD, India, July 26, 2021/ PRNewswire/– Sai Life Sciences, among India &’s fastest growing Contract Research, Development & Manufacturing Organizations(CRDMOs), today announced that it has been honoured with the Golden Peacock National Training Award 2021 in the pharmaceutical classification. This is the 2nd successive Golden Peacock Award for the business following the Golden Peacock…